Galectin Therapeutics reported $14.62M in Current Liabilities for its fiscal quarter ending in June of 2024.





Current Liabilities Change Date
AbbVie USD 42.1B 1.19B Mar/2026
Bristol-Myers Squibb USD 19.16B 4.26B Mar/2026
Galectin Therapeutics USD 14.62M 1.98M Jun/2024
Gilead Sciences USD 9.48B 2.34B Mar/2026
Immunic USD 38.36M 7.74M Mar/2026
Incyte USD 1.49B 25.52M Mar/2026
Merck USD 26.94B 1.38B Mar/2026